Necrotizing pancreatitis is a condition where parts of the pancreas die and may get infected, such complication is called as acute pancreatitis. Necrotizing pancreatitis occurs when pancreatic tissue dies due to inflammation.
Changing lifestyle patterns and increase in the number of patients suffering from liver problems and rise in demand for advanced treatment are major factors expected to drive the growth of the global dead pancreatic tissue treatment market. In Europe and North America, 50% of acute pancreatitis cases are caused by gallstones, and 25% are caused by alcohol. In 2017, there were an estimated 78,969 people living with pancreatic cancer in the United States. The rate of new cases of pancreatic cancer was 13.1 per 100,000 men and women per year. High investment by major players for development of advanced medical devices that aid in surgeries, along with availability of advanced infrastructure for R&D activities and introduction of innovative solutions from major players are factors expected to boost the growth of dead pancreatic tissue treatment market.
In 2020, the U.S. Food and Drug Administration authorized marketing of the EndoRotor System to resect (cut out) and remove necrotic (dead) tissue for patients with walled-off pancreatic necrosis (WOPN). The marketing of the product is granted to Interscope Incorporated a medical device company.
In 2016, Boston Scientific Corporation a global medical device manufacturing company launched AXIOS™ Stent and Electrocautery Enhanced Delivery System to help physicians manage serious complications from pancreatitis using a minimally invasive endoscopic approach. This product launch is expected to help the company to enhance the business presence and increase the revenue share.
Major players focus on business expansion through strategic acquisition and focus on increasing the customer base and product offerings is important factor expected to impact the growth of dead pancreatic tissue treatment market.
In 2017, EnteroMedics Inc. a medical device manufacturer acquired Gastric Vest System. Gastric Vest System deals with investigational, minimally-invasive, a laparoscopically implanted medical device that are being studied for weight loss in morbidly obese patients. This acquisition is expected to help the company to enhance the business and increase the product portfolio.
Players are focused on tracing the untapped market in emerging economies. Favorable business policies by the government of developing countries are attracting manufacturers across the globe. Players are shifting the manufacturing units to developing countries due to easy availability of raw material and low cost labor. These factors are cumulatively responsible for the target market growth. Factors such as stringent government regulations related to product approval and high cost associated to surgery are expected to hamper the growth of global dead pancreatic tissue treatment market. In addition, lack of developed infrastructure in developing countries is limiting the adoption of advanced devices is expected to challenge the growth of target market. However, high investment by major players for R&D activities, focus on integration of AI in medical devices and introduction of innovative solutions are factors expected to create new opportunities for players operating in the dead pancreatic tissue treatment market over the forecast period.
In addition, increasing partnership and agreement activities is expected to further support the growth of target market.
Segment Analysis by Region
The market in North America is expected to account for major revenue share in the global dead pancreatic tissue treatment market due to high patient pool suffering from pancreas problems. In addition, high spending capacity, availability of advanced infrastructure and favorable reimbursement policies are factors expected to segment the growth of dead pancreatic tissue treatment market.
The market in Asia Pacific is expected to witness faster growth in the dead pancreatic tissue treatment market due to increasing awareness among consumers related to pancreas cancer. In addition, government awareness activities related to advanced treatment and introduction of innovative solution from regional players is expected to boost the target market growth.
The global dead pancreatic tissue treatment market is high highly competitive due to presence of large number of players and innovative product offerings. In addition, business expansion activities through partnerships and agreements are factors expected to further increase the competition. The players profiled in the report are CalciMedica, SCM Lifescience, Samsung Bioepis, GNT Pharma Co., Baxter International Inc., B. Braun Melsungen AG, General Electric Company, Medtronic, Boston Scientific Corporation, and Fresenius Kabi USA.
Dead Pancreatic Tissue Treatment Market Segment Analysis, 2019
The global dead pancreatic tissue treatment market is segmented into treatment type and end use. The treatment type segment is bifurcated into intravenous fluid, nutritional support, analgesics, endoscopic retrograde cholangiopancreatography (ERCP), and others. The end use segment is divided into hospitals & clinics and others. Among the end use the hospital & clinics segment is expected to account for major revenue share in the dead pancreatic tissue treatment market.
Market By Treatment Type
Endoscopic Retrograde Cholangiopancreatography (ERCP)
Market By End Use
Hospitals & Clinics
Market By Geography
• Rest of Europe
• South Korea
• Rest of Asia-Pacific
• Rest of Latin America
Middle East & Africa
• South Africa
• Rest of Middle East & Africa
Chancing lifestyle pattern and increase in number of inpatients suffering from liver problems and rise in demand for advanced treatment are major factors expected to drive the growth of global dead pancreatic tissue treatment market.
In treatment type the endoscopic retrograde cholangiopancreatography (ERCP) segment is growing at faster pace.
In the global market, Asia Pacific is expected to grow faster.
Some of the players considered in the report scope are CalciMedica, SCM Lifescience, Samsung Bioepis, GNT Pharma Co., and Baxter International Inc.
The North America is expected to account for major revenue share in the global market.
In end use the hospital segment is growing at faster pace.
Factors such as stringent government regulations related to product approval and high cost associated to surgery are expected to hamper the growth of global dead pancreatic tissue treatment market.